Edition:
United States

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

43.45USD
3:43pm EDT
Change (% chg)

$0.45 (+1.05%)
Prev Close
$43.00
Open
$42.80
Day's High
$44.10
Day's Low
$42.80
Volume
71,954
Avg. Vol
289,476
52-wk High
$68.05
52-wk Low
$24.05

Chart for

About

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The... (more)

Overall

Beta: --
Market Cap(Mil.): $2,288.51
Shares Outstanding(Mil.): 50.13
Dividend: --
Yield (%): --

Financials

  GBT.OQ Industry Sector
P/E (TTM): -- 185.16 33.25
EPS (TTM): -2.75 -- --
ROI: -45.24 -0.71 13.13
ROE: -46.34 -2.76 14.96

BRIEF-Global Blood Therapeutics ‍priced underwritten public offering of 4.0 mln shares of its common stock

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF 4,000,000 SHARES OF COMMON STOCK

Mar 08 2018

BRIEF-Global Blood Therapeutics Announces Proposed Public Offering

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 08 2018

BRIEF-GBT Appoints David Johnson As Chief Commercial Officer

* GBT APPOINTS INDUSTRY LEADER DAVID L. JOHNSON AS CHIEF COMMERCIAL OFFICER Source text for Eikon: Further company coverage:

Mar 06 2018

BRIEF-Global Blood Therapeutics Q4 Loss Per Share $0.94

* GBT REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease

* GBT RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE (SCD) Source text for Eikon: Further company coverage:

Jan 09 2018

BRIEF-Global Blood Therapeutics Prices A $100.0 Mln Common Stock Public Offering

* GLOBAL BLOOD THERAPEUTICS PRICES A $100.0 MILLION COMMON STOCK PUBLIC OFFERING Source text for Eikon: Further company coverage:

Dec 15 2017

BRIEF-Global Blood Therapeutics To Sell $100 Mln In Public Offering Of Shares

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Dec 14 2017

BRIEF-Global Blood Therapeutics says DSMB safety review for phase 3 HOPE study completed

* Global Blood Therapeutics announces completion of safety review by independent data and safety monitoring board (DSMB) for phase 3 HOPE study in sickle cell disease Source text for Eikon: Further company coverage:

Nov 13 2017

BRIEF-Global Blood Therapeutics posts Q3 loss per share $0.66

* Global Blood Therapeutics reports recent business progress and provides third quarter 2017 financial results

Nov 02 2017

BRIEF-Global blood Therapeutics reports approval of voxelotor as nonproprietary name for GBT440

* Global Blood Therapeutics announces approval of first-in-class “voxelotor” as nonproprietary name for gbt440

Oct 24 2017

Competitors

  Price Chg
Bristol-Myers Squibb Co (BMY.N) $51.15 -0.47
Bristol-Myers Squibb Co (BMYMP.PK) $1,306.55 --
Novartis AG (NOVN.S) CHF76.08 -1.20
bluebird bio Inc (BLUE.OQ) $171.15 +0.65
Pfizer Inc. (PFE.N) $36.53 +0.00
Roche Holding Ltd. (ROG.S) CHF215.65 -0.85
Roche Holding Ltd. (RO.S) CHF220.00 -0.20

Earnings vs. Estimates